Myelodysplastic Syndromes: all 2,165 studies
Page 17 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic MalignanciesCompletedNCT01175785Phase 2
- Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT01174888Phase 1
- PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute LeukemiasCompletedNCT01169012Phase 1
- INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative DiseaseCompletedNCT01164163Phase 1
- Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDSCompletedNCT01159028Phase 1
- Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) PatientsCompletedNCT01152346Phase 1
- Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced LeukemiasCompletedNCT01149915Phase 1
- Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01146210
- Blood Samples to Identify Biomarkers in Haploidentical Graft RecipientsCompletedNCT01141959
- B-Receptor Signaling in CardiomyopathyCompletedNCT01135849
- Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) FailureStatus unknownNCT01133886Phase 2
- Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01132586Phase 1
- Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01130506Phase 1
- Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic SyndromesStatus unknownNCT01129739Phase 2
- Temsirolimus in Myelodysplastic Syndrome (MDS)TerminatedNCT01111448Phase 2
- Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With MalignanciesWithdrawnNCT01101412Phase 1/2
- Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional StudyCompletedNCT01095874
- Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5qCompletedNCT01088373Phase 2
- Erlotinib in Higher Risk Myelodysplastic SyndromeCompletedNCT01085838Phase 1/2
- A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDSTerminatedNCT01085656Phase 1
- Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5qCompletedNCT01081431Phase 2
- Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell TransplantTerminatedNCT01077440
- Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic SyndromeCompletedNCT01075425Phase 1
- A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell TransplantationCompletedNCT01068301Phase 1
- Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)CompletedNCT01065129Phase 1
- Clofarabine in High Risk Myelodysplastic Syndrome (MDS)CompletedNCT01063257Phase 1/2
- Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)CompletedNCT01062490Phase 2
- Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)CompletedNCT01062152Phase 1
- Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid MalignanciesCompletedNCT01056614Phase 2
- Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic SyndromeStatus unknownNCT01053806Phase 2
- Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
- Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic SyndromeCompletedNCT01048619Phase 1
- Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)CompletedNCT01048034Phase 2
- MSC and HSC Coinfusion in Mismatched MinitransplantsTerminatedNCT01045382Phase 2
- A Study for Dacogen Treatment in Patients With Myelodysplastic SyndromeCompletedNCT01041846
- Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.TerminatedNCT01039350Phase 2
- Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic SyndromesTerminatedNCT01029509Phase 1
- An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)No longer availableNCT01026376
- Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk LeukemiaCompletedNCT01020539Phase 1
- Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell TransplantationCompletedNCT01020175Phase 3
- Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)CompletedNCT01015352Phase 2
- Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) PatientsSuspendedNCT01010373Phase 2
- Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic SyndromeTerminatedNCT01009502Phase 1
- Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic PatientsTerminatedNCT01003678Phase 1
- Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body IrradiationTerminatedNCT00996359Phase 1
- S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic CancersCompletedNCT00996047
- Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With DapsoneCompletedNCT00993694
- Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic MalignancyCompletedNCT00990587Phase 1
- Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeCompletedNCT00988715Phase 1
- Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High RiskCompletedNCT00987584
- Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post TransplantCompletedNCT00986804Phase 1
- Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic SyndromesCompletedNCT00981240Phase 1
- Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic SyndromeTerminatedNCT00977132Phase 2
- Survey on QUality of Life In myeloDisplasia (SQUID)CompletedNCT00967564
- Intraosseous Infusion of Unrelated Cord Blood GraftsTerminatedNCT00967525Not applicable
- SCRI Tissue Testing RegistryTerminatedNCT00965861
- Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell TransplantCompletedNCT00964821
- Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological MalignancyTerminatedNCT00963495Phase 1
- NOV-002 in Myelodysplastic Syndrome (MDS)WithdrawnNCT00960726Phase 2
- Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)Status unknownNCT00956787Phase 2
- Observational Study of Iron Overload in Stem Cell TransplantationCompletedNCT00954720
- Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy VolunteersTerminatedNCT00952185Not applicable
- A Standardized Nursing Intervention Protocol for HCT PatientsCompletedNCT00951626Not applicable
- Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic SyndromeTerminatedNCT00946283Not applicable
- Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)CompletedNCT00941109Phase 1
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT00935090
- Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic SyndromesTerminatedNCT00923234Phase 1
- S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic CancerCompletedNCT00919425
- A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic SyndromeCompletedNCT00916227Phase 1
- Pilot Study of Unrelated Cord Blood TransplantationTerminatedNCT00916045Phase 2
- Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and ThymoglobulinTerminatedNCT00915811Phase 2
- Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic AbnormalitiesCompletedNCT00915785Phase 2
- MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic LeukemiaCompletedNCT00911066Phase 1
- Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative DiseasesCompletedNCT00909467
- Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic MalignanciesCompletedNCT00908167Phase 1
- Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High RiskCompletedNCT00906334Phase 2
- Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)CompletedNCT00903422Phase 1
- Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell TransplantCompletedNCT00900406
- Collecting and Storing Blood Samples From Patients With CancerWithdrawnNCT00900120
- Blood Samples From Patients on a Clinical Trial to CINV During HSCTTerminatedNCT00900068
- Studying Fentanyl in Patients With CancerTerminatedNCT00899951
- Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy VolunteersCompletedNCT00899795
- Proteases in Patients With Prostate Cancer That Has Spread to the BoneCompletedNCT00899665
- Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy ParticipantsStatus unknownNCT00899327
- Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic SyndromesActive, not recruitingNCT00899223
- Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell TransplantStatus unknownNCT00898118
- 5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs)CompletedNCT00897130Phase 2
- Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic SyndromeCompletedNCT00892190Phase 1
- Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic MalignancyCompletedNCT00891137Phase 1
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and NeutropeniaWithdrawnNCT00886496Phase 1
- A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5qStatus unknownNCT00885508Phase 2
- Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)CompletedNCT00875745Phase 1
- A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)CompletedNCT00875693Phase 1
- The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) AbnormalityCompletedNCT00874978Phase 2
- Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed DiseaseCompletedNCT00871702Phase 1
- FTS Study in Patients With Advanced Hematologic MalignanciesCompletedNCT00867230Phase 1
- Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)WithdrawnNCT00867061Phase 1/2
- Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AMLCompletedNCT00854945Phase 1/2